Novel Therapies to Inhibit Mucus Synthesis and Secretion in Airway Hypersecretory Diseases

Pharmacology

Volumn 97, Issue 1-2, 2016, Pages 84-100

  Ha, Emily V S ^a   Rogers, Duncan F ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Airways; Asthma; Bio 11006; Chronic obstructive pulmonary disease; Epidermal growth factor receptor; Macrolides; MARCKS; Mucin; Mucus

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; CLCA1 INHIBITOR; ELLAGIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GINKGOLIDE B; HEAT SHOCK PROTEIN 70 INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1 INHIBITOR; INTERLEUKIN 13; MACROLIDE; MARCKS BLOCKADE; MARCKS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 13; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; MUCIN; MUNC INHIBITOR; P2Y2 AGONIST; P2Y2 ANTAGONIST; PROTEIN INHIBITOR; SOLUBLE NSF ATTACHMENT PROTEIN PECEPTORS CLEAVAGE; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; AUTACOID; CHLORIDE CHANNEL; CLCA1 PROTEIN, HUMAN; GINKGOLIDE; HEAT SHOCK PROTEIN 70; LACTONE; MEMBRANE PROTEIN; MUNC18 PROTEIN; MYRISTOYLATED ALANINE-RICH C KINASE SUBSTRATE; PROTEIN TYROSINE KINASE; PURINERGIC P2Y RECEPTOR; SIGNAL PEPTIDE;

AIRWAY REMODELING; ASTHMA; CELL HYPERPLASIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; GENE EXPRESSION; GOBLET CELL HYPERPLASIA; HUMAN; IMMUNOTHERAPY; MUCUS SECRETION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; RESPIRATORY TRACT INFLAMMATION; REVIEW; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; METABOLISM; MUCUS; PHYSIOLOGY; SECRETION (PROCESS);

AIRWAY REMODELING; ASTHMA; CHLORIDE CHANNELS; ELLAGIC ACID; GABA ANTAGONISTS; GINKGOLIDES; HSP70 HEAT-SHOCK PROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOXIA-INDUCIBLE FACTOR 1; INFLAMMATION MEDIATORS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LACTONES; MACROLIDES; MEMBRANE PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 13; MUCINS; MUCUS; MUNC18 PROTEINS; PROTEIN-TYROSINE KINASES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PURINERGIC P2Y;

EID: 84955208955     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000442794     Document Type: Review

References (81)

1. Rogers DF: Physiology of airway mucus secretion and pathophysiology of hypersecretion. Respir Care 2007;52:1134-1146.
2. Evans CM, Kim K, Tuvim MJ, Dickey BF: Mucus hypersecretion in asthma: causes and effects. Curr Opin Pulm Med 2009;15:4-11.
3. Evans CM, Koo JS: Airway mucus: the good, the bad, the sticky. Pharmacol Ther 2009;121:332-348.
4. Rose MC, Voynow JA: Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 2006;86:245-278.
5. Ferkol T, Schraufnagel D: The global burden of respiratory disease. Ann Am Thorac Soc 2014;11:404-406.
6. Burney P, Jarvis D, Perez-Padilla R: The global burden of chronic respiratory disease in adults. Int J Tuberc Lung Dis 2015;19:10-20.
7. Cazzola M, Page CP, Calzetta L, Matera MG: Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012;64:450-504.
8. Hakim A, Adcock IM, Usmani OS: Corticosteroid resistance and novel anti-inflammatory therapies in chronic obstructive pulmonary disease: current evidence and future direction. Drugs 2012;72:1299-1312.
9. Tildy BE, Rogers DF: Therapeutic options for hydrating airway mucus in cystic fibrosis. Pharmacology 2015;95:117-132.
10. McConnell W, Holgate S: The definition of asthma: its relationship to other chronic obstructive lung diseases; in Clark T, Godfrey S, Lee T, Thomson N (eds): Asthma, ed 4. USA, Arnold, 2000, pp 7-25.
11. Rubin BK, Priftis KN, Schmidt HJ, Henke MO: Secretory hyperresponsiveness and pulmonary mucus hypersecretion. Chest 2014;146:496-507.
12. McCarty JC, Ferguson BJ: Identifying asthma triggers. Otolaryngol Clin North Am 2014;47:109-118.
13. Maslan J, Mims JW: What is asthma? Pathophysiology, demographics, and health care costs. Otolaryngol Clin North Am 2014;47:13-22.
14. Rothenberg ME, Hogan SP: The eosinophil. Annu Rev Immunol 2006;24:147-174.
15. Nakagome K, Matsushita S, Nagata M: Neutrophilic inflammation in severe asthma. Int Arch Allergy Immunol 2012;158(suppl 1):96-102.
16. Wang Y, Bai C, Li K, Adler KB, Wang X: Role of airway epithelial cells in development of asthma and allergic rhinitis. Respir Med 2008;102:949-955.
17. Rogers DF, Barnes PJ: Treatment of airway mucus hypersecretion. Ann Med 2006;38:116-125.
18. Bradding P, Walls AF, Holgate ST: The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 2006;117:1277-1284.
19. Theander K, Hasselgren M, Luhr K, Eckerblad J, Unosson M, Karlsson I: Symptoms and impact of symptoms on function and health in patients with chronic obstructive pulmonary disease and chronic heart failure in primary health care. Int J Chron Obstruct Pulmon Dis 2014;9:785-794.
20. Hassett DJ, Borchers MT, Panos RJ: Chronic obstructive pulmonary disease (COPD): evaluation from clinical, immunological and bacterial pathogenesis perspectives. J Microbiol 2014;52:211-226.
21. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the medical research council by their committee on the aetiology of chronic bronchitis. Lancet 1965;1:775-779.
22. van den Berge M, ten Hacken NH, Cohen J, Douma WR, Postma DS: Small airway disease in asthma and COPD: clinical implications. Chest 2011;139:412-423.
23. MacNee W: Pathology, pathogenesis, and pathophysiology. BMJ 2006;332:1202-1204.
24. Bradley JR: TNF-mediated inflammatory disease. J Pathol 2008;214:149-160.
25. Barnes PJ: Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med 2014;35:71-86.
26. de Oliveira S, Reyes-Aldasoro CC, Candel S, Renshaw SA, Mulero V, Calado A: Cxcl8 (IL-8) mediates neutrophil recruitment and behavior in the zebrafish inflammatory response. J Immunol 2013;190:4349-4359.
27. Williams OW, Sharafkhaneh A, Kim V, Dickey BF, Evans CM: Airway mucus: from production to secretion. Am J Respir Cell Mol Biol 2006;34:527-536.
28. Nadel JA, Burgel PR: The role of epidermal growth factor in mucus production. Curr Opin Pharmacol 2001;1:254-258.
29. Nadel JA: Role of epidermal growth factor receptor activation in regulating mucin synthesis. Respir Res 2001;2:85-89.
30. Takeyama K, Dabbagh K, Lee HM, Agustí C, Lausier JA, Ueki IF, et al: Epidermal growth factor system regulates mucin production in airways. Proc Natl Acad Sci U S A 1999;96:3081-3086.
31. Fu XW, Wood K, Spindel ER: Prenatal nicotine exposure increases GABA signaling and mucin expression in airway epithelium. Am J Respir Cell Mol Biol 2011;44:222-229.
32. Glasser MA: GABAergic system as a target for treatment in asthma. Thorax 2007;62:1080.
33. Yu H, Li Q, Kolosov VP, Perelman JM, Zhou X: Regulation of cigarette smoke-mediated mucin expression by hypoxia-inducible factor-1α via epidermal growth factor receptor-mediated signaling pathways. J Appl Toxicol 2012;32:282-292.
34. Polosukhin VV, Cates JM, Lawson WE, Milstone AP, Matafonov AG, Massion PP, et al: Hypoxia-inducible factor-1 signalling promotes goblet cell hyperplasia in airway epithelium. J Pathol 2011;224:203-211.
35. Crotty Alexander LE, Akong-Moore K, Feldstein S, Johansson P, Nguyen A, McEachern EK, et al: Myeloid cell HIF-1α regulates asthma airway resistance and eosinophil function. J Mol Med 2013;91:637-644.
36. Adler KB, Tuvim MJ, Dickey BF: Regulated mucin secretion from airway epithelial cells. Front Endocrinol (Lausanne) 2013;4:129.
37. Agrawal A, Rengarajan S, Adler KB, Ram A, Ghosh B, Fahim M, et al: Inhibition of mucin secretion with MARCKS-related peptide improves airway obstruction in a mouse model of asthma. J Appl Physiol (1985) 2007;102:399-405.
38. Rogers DF: Motor control of airway goblet cells and glands. Respir Physiol 2001;125:129-144.
39. Nadel JA, Davis B, Phipps RJ: Control of mucus secretion and ion transport in airways. Annu Rev Physiol 1979;41:369-381.
40. Dittrich C, Greim G, Borner M, Weigang-Köhler K, Huisman H, Amelsberg A, et al: Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer 2002;38:1072-1080.
41. Hur GY, Lee SY, Lee SH, Kim SJ, Lee KJ, Jung JY, et al: Potential use of an anticancer drug gefinitib, an EGFR inhibitor, on allergic airway inflammation. Exp Mol Med 2007;39:367-375.
42. Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A: Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane. J Am Acad Dermatol 2015;72:203-218.
43. Woodruff PG, Wolff M, Hohlfeld JM, Krug N, Dransfield MT, Sutherland ER, et al: Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;181:438-445.
44. Alevy YG, Patel AC, Romero AG, Patel DA, Tucker J, Roswit WT, et al: IL-13-induced airway mucus production is attenuated by MAPK13 inhibition. J Clin Invest 2012;122:4555-4568.
45. Chung KF: p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest 2011;139:1470-1479.
46. Hauber HP, Zabel P: Emerging mucus regulating drugs in inflammatory and allergic lung disease. Inflamm Allergy Drug Targets 2008;7:30-34.
47. Hauber HP, Daigneault P, Frenkiel S, Lavigne F, Hung HL, Levitt RC, et al: Niflumic acid and MSI-2216 reduce TNF-alpha-induced mucin expression in human airway mucosa. J Allergy Clin Immunol 2005;115:266-271.
48. Nakano T, Inoue H, Fukuyama S, Matsumoto K, Matsumura M, Tsuda M, et al: Niflumic acid suppresses interleukin-13-induced asthma phenotypes. Am J Respir Crit Care Med 2006;173:1216-1221.
49. Robichaud A, Tuck SA, Kargman S, Tam J, Wong E, Abramovitz M, et al: Gob-5 is not essential for mucus overproduction in preclinical murine models of allergic asthma. Am J Respir Cell Mol Biol 2005;33:303-314.
50. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, et al: YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003;95:516-525.
51. Zhou X, Tu J, Li Q, Kolosov VP, Perelman JM: Hypoxia induces mucin expression and secretion in human bronchial epithelial cells. Transl Res 2012;160:419-427.
52. Tsui L, Fong TH, Wang IJ: The effect of 3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole (YC-1) on cell viability under hypoxia. Mol Vis 2013;19:2260-2273.
53. Van Cutsem E, Köhne C, Hitre E, Zaluski J, Chang Chien C, Makhson A, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-1417.
54. Shen HH, Xu F, Zhang GS, Wang SB, Xu WH: CCR3 monoclonal antibody inhibits airway eosinophilic inflammation and mucus overproduction in a mouse model of asthma. Acta Pharmacol Sin 2006;27:1594-1599.
55. Ross CL, Hansel TT: New drug therapies for COPD. Clin Chest Med 2014;35:219-239.
56. Criner G, Connett JE, Aaron SD, Albert RK, Bailey WC, Casaburi R, et al: Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 2014;370:2201-2210.
57. Marin L, Traini D, Bebawy M, Colombo P, Buttini F, Haghi M, et al: Multiple dosing of simvastatin inhibits airway mucus production of epithelial cells: implications in the treatment of chronic obstructive airway pathologies. Eur J Pharm Biopharm 2013;84:566-572.
58. Zeki AA, Bratt JM, Rabowsky M, Last JA, Kenyon NJ: Simvastatin inhibits goblet cell hyperplasia and lung arginase in a mouse model of allergic asthma: a novel treatment for airway remodeling? Transl Res 2010;156:335-349.
59. Zeki AA, Franzi L, Last J, Kenyon NJ: Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med 2009;180:731-740.
60. Liou CJ, Cheng PY, Huang WC, Chan CC, Chen MC, Kuo ML, et al: Oral lovastatin attenuates airway inflammation and mucus secretion in ovalbumin-induced murine model of asthma. Allergy Asthma Immunol Res 2014;6:548-557.
61. Zhu T, Zhang W, Wang DX, Huang NW, Bo H, Deng W, et al: Rosuvastatin attenuates mucus secretion in a murine model of chronic asthma by inhibiting the gamma-aminobutyric acid type A receptor. Chin Med J (Engl) 2012;125:1457-1464.
62. Neukamm A, Høiseth AD, Einvik G, Lehmann S, Hagve TA, Søyseth V, et al: Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial. J Intern Med 2015;278:59-67.
63. Blamoun AI, Batty GN, DeBari VA, Rashid AO, Sheikh M, Khan MA: Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract 2008;62:1373-1378.
64. Keddissi JI, Younis WG, Chbeir EA, Daher NN, Dernaika TA, Kinasewitz GT: The use of statins and lung function in current and former smokers. Chest 2007;132:1764-1771.
65. Law M, Rudnicka AR: Statin safety: a systematic review. Am J Cardiol 2006;97(8 suppl 1):S52-S60.
66. Zhou E, Fu Y, Wei Z, Yang Z: Inhibition of allergic airway inflammation through the blockage of NF-κB activation by ellagic acid in an ovalbumin-induced mouse asthma model. Food Funct 2014;5:2106-2112.
67. Alves Cde F, Angeli GN, Favarin DC, de Andrade EL, Chica JE, Faccioli LH, et al: The effects of proresolution of ellagic acid in an experimental model of allergic airway inflammation. Mediators Inflamm 2013;2013:863198.
68. Chu X, Ci X, He J, Wei M, Yang X, Cao Q, et al: A novel anti-inflammatory role for ginkgolide B in asthma via inhibition of the ERK/MAPK signaling pathway. Molecules 2011;16:7634-7648.
69. Li MH, Zhang HL, Yang BY: [Effects of ginkgo leave concentrated oral liquor in treating asthma]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1997;17:216-218.
70. Green TD, Crews AL, Park J, Fang S, Adler KB: Regulation of mucin secretion and inflammation in asthma: a role for MARCKS protein? Biochim Biophys Acta 2011;1810:1110-1113.
71. Van As A, Kraft M, Hanania NA, Parikh I, Murphy EC: Inhibition of airway mucus hypersecretion and inflammation with Bio-11006, a novel dual action drug, results in improvement of indices of bronchitis and lung function in chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 2011;183:A4092.
72. Fang S, Crews AL, Chen W, Park J, Yin Q, Ren XR, et al: MARCKS and HSP70 interactions regulate mucin secretion by human airway epithelial cells in vitro. Am J Physiol Lung Cell Mol Physiol 2013;304:L511-L518.
73. Rogers DF: The role of airway secretions in COPD: pathophysiology, epidemiology and pharmacotherapeutic options. COPD 2005;2:341-353.
74. Kannan K, Kanabar P, Schryer D, Florin T, Oh E, Bahroos N, et al: The general mode of translation inhibition by macrolide antibiotics. Proc Natl Acad Sci U S A 2014;111:15958-15963.
75. Lu S, Liu H, Farley JM Sr: Macrolide antibiotics inhibit mucus secretion and calcium entry in Swine airway submucosal mucous gland cells. J Pharmacol Exp Ther 2011;336:178-187.
76. Shimizu T, Shimizu S, Hattori R, Gabazza EC, Majima Y: In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. Am J Respir Crit Care Med 2003;168:581-587.
77. Shimizu T, Shimizu S: Azithromycin inhibits mucus hypersecretion from airway epithelial cells. Mediators Inflamm 2012;2012:265714.
78. Tanabe T, Kanoh S, Tsushima K, Yamazaki Y, Kubo K, Rubin BK: Clarithromycin inhibits interleukin-13-induced goblet cell hyperplasia in human airway cells. Am J Respir Cell Mol Biol 2011;45:1075-1083.
79. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, et al: Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-698.
80. Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, et al: Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013;68:322-329.
81. Liu L, Wang GZ, Han D, Li MX: Effectiveness and safety of azithromycin in the treatment of bronchial asthma: a meta-analysis. Nan Fang Yi Ke Da Xue Xue Bao 2015;35:83-87.